Joe Walsh, 79, has become the first person living with Alzheimer’s to receive an experimental nasal spray treatment aimed at reducing inflammation in the brain. The monoclonal antibody, foralumab, is being tested not only in patients with Alzheimer’s but also in those with multiple sclerosis, ALS, and COVID-19.
The treatment involves inhaling a fine mist containing the medication through a nasal spray applicator. Researchers report that it has successfully reduced inflammation in Walsh’s brain, according to data from the Clinical Nuclear Medicine journal.
While this reduction in inflammation may not necessarily translate to improved cognitive function, researchers believe that addressing this aspect of Alzheimer’s disease could be key to slowing its progression. Current treatments focus on clearing sticky amyloid plaques and tangled fibers called tau from the brain.
Walsh’s case highlights the challenges faced by patients with Alzheimer’s in accessing new treatments due to the pandemic shutdown of research studies. The experimental treatment was made possible through a special FDA program for patients who cannot participate in clinical trials.
After six months on the treatment, Walsh’s inflammation levels have decreased significantly. However, his memory and thinking remain impaired, as is typical with Alzheimer’s. Nevertheless, his wife Karen reports some positive changes, including increased engagement in social activities and improved mood.
The results of a clinical trial scheduled for later this year will provide further insight into the effectiveness of foralumab in reducing inflammation and improving cognitive function in patients with Alzheimer’s.
Source: https://www.npr.org/sections/shots-health-news/2025/05/30/nx-s1-5407860/alzheimers-nasal-spray-experimental-treatment